



Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015
Tel. No.: (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com
CIN : L24230GJ1995PLC025878

PART I

Statement of Results for the Quarter and Nine Months Ended 31/12/2014

Rupees in Lacs							Sr. No.	Particulars	Rupees in Lacs					
CONSOLIDATED						COMPANY								
3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/03/2014	3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/03/2014			
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
219,791	210,633	187,253	636,104	525,636	720,834	126,780	113,600	91,369	340,752	258,255	358,733			
3,837	4,280	3,449	11,759	11,262	14,827	2,413	1,805	1,656	5,899	4,844	6,280			
215,954	206,353	183,804	624,345	514,374	706,007	124,367	111,795	89,713	334,853	253,411	352,453			
2,992	4,447	3,365	10,413	11,179	16,396	22,121	13,486	13,035	48,195	40,646	51,758			
218,946	210,800	187,169	634,758	525,553	722,403	146,488	125,281	102,748	383,048	294,057	404,211			
47,088	50,473	41,058	144,614	120,926	162,882	31,301	35,972	26,400	98,928	80,141	106,814			
32,303	35,629	31,136	108,556	81,810	115,430	10,762	9,185	9,853	31,484	27,686	38,266			
(3,479)	(3,894)	(157)	(13,718)	(9,136)	(6,949)	(536)	(1,337)	(814)	(7,062)	(3,603)	(3,571)			
31,704	28,727	26,147	89,444	79,754	107,111	16,209	14,319	12,717	45,704	39,211	52,514			
7,072	7,329	4,957	21,171	14,845	20,123	5,127	5,224	3,237	15,646	9,523	12,740			
66,609	57,766	59,459	181,431	168,040	223,915	40,415	34,749	35,952	106,879	97,410	129,489			
181,297	176,030	162,600	531,498	456,239	622,512	103,278	98,112	87,345	291,579	250,368	336,252			
37,649	34,770	24,569	103,260	69,314	99,891	43,210	27,169	15,403	91,469	43,689	67,959			
1,001	1,461	1,278	3,503	3,754	5,067	1,018	14,379	6,000	17,031	28,824	30,859			
38,650	36,231	25,847	106,763	73,068	104,958	44,228	41,548	21,403	108,500	72,513	98,818			
1,624	1,726	1,898	5,158	6,615	9,019	1,050	1,023	780	2,898	3,250	4,251			
37,026	34,505	23,949	101,605	66,453	95,939	43,178	40,525	20,623	105,602	69,263	94,567			
(461)	(23)	347	(366)	347	1,715	0	0	0	0	0	0			
37,487	34,528	23,602	101,971	66,106	94,224	43,178	40,525	20,623	105,602	69,263	94,567			
7,910	5,713	4,083	18,867	7,125	10,601	7,062	3,964	1,130	13,196	572	4,208			
29,577	28,815	19,519	83,104	58,981	83,623	36,116	36,561	19,493	92,406	68,691	90,359			
0	0	0	0	0	0	0	0	0	0	0	0			
29,577	28,815	19,519	83,104	58,981	83,623	36,116	36,561	19,493	92,406	68,691	90,359			
0	0	0	0	0	0	0	0	0	0	0	0			
(1,386)	(1,006)	(922)	(3,083)	(2,541)	(3,264)	0	0	0	0	0	0			
28,191	27,809	18,597	80,021	56,440	80,359	36,116	36,561	19,493	92,406	68,691	90,359			
10,237	10,237	10,237	10,237	10,237	10,237	10,237	10,237	10,237	10,237	10,237	10,237			
					333,662						352,754			
13.77	13.58	9.08	39.08	27.57	39.25	17.64	17.86	9.52	45.13	33.55	44.13			
13.77	13.58	9.08	39.08	27.57	39.25	17.64	17.86	9.52	45.13	33.55	44.13			
13.77	13.58	9.08	39.08	27.57	39.25	17.64	17.86	9.52	45.13	33.55	44.13			
13.77	13.58	9.08	39.08	27.57	39.25	17.64	17.86	9.52	45.13	33.55	44.13			

Notes :

- [1] The above results for the quarter/ nine months ended on December 31, 2014 were reviewed by the Audit Committee on February 9, 2015 and then approved by the Board of Directors at their meeting held on February 10, 2015.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] Effective from April 1, 2014, the Company has changed the depreciation charge based on the revised remaining useful lives of the assets as per the requirement of Schedule II of the Companies Act, 2013. Due to this, the depreciation charge for the quarter ended December 31, 2014 is higher by Rs. 1,613 Lacs on Standalone basis [Rs. 1,649 Lacs on Consolidated basis] and for the nine months ended December 31, 2014 is higher by Rs. 4,839 Lacs on Standalone basis [Rs. 5,325 Lacs on Consolidated basis]. Further, based on transitional provision provided in Note 7(b) of Schedule II, an amount of Rs. 2,497 Lacs on Standalone basis [Rs.2,594 Lacs on Consolidated basis], which pertains to the carrying value of the assets whose remaining useful lives as on April 1, 2014 is "Nil", has been adjusted to the Retained Earnings.
- [4] Exceptional items in the consolidated results include:

No.	Particulars	Rupees in Lacs					
		3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/03/2014
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
a	Provision for various expenses related to the closure of business operations in Japan	22	(23)	347	117	347	1,715
b	Provision for amount payable to a former supplier for termination of supply contract, pursuant to the order passed by the Hon'able High Court of Madrid, Spain	1,070	0	0	1,070	0	0
c	Credit of additional excise duty [for the years 2011-12 to 2013-14] received by M/s. Zydus Wellness, Sikkim, pursuant to the order passed by the Office of the Commissioner of Customs, Central Excise and Service Tax for the fixation of special rates of excise duty for the said 3 years	(1,553)	0	0	(1,553)	0	0

- [5] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [6] The Company has one segment of activity viz., "Pharmaceuticals".

PART II

Select information for the Quarter and Nine Months Ended 31/12/2014

3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/03/2014	Particulars	3 Months ended 31/12/2014	Preceding 3 months ended 30/09/2014	Corresponding 3 months ended 31/12/2013 in the previous year	Year to date figures for the current period ended 31/12/2014	Year to date figures for the previous year ended 31/12/2013	Previous year ended 31/03/2014
51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474	A						
25.21%	25.21%	25.21%	25.21%	25.21%	25.21%	1	PARTICULARS OF SHAREHOLDING					
							Public shareholding					
							- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474
							- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%	25.21%
							2					
							Promoters and Promoter Group Shareholding					
							a					
							Pledged / Encumbered					
Nil	Nil	Nil	Nil	Nil	Nil		- Number of shares	Nil	Nil	Nil	Nil	Nil
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.		- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	N.A.	N.A.	N.A.	N.A.	N.A.
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.		- Percentage of shares (as a % of the total share capital of the company)	N.A.	N.A.	N.A.	N.A.	N.A.
							b					
							Non - encumbered					
153,138,046	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046		- Number of shares	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046
100.00%	100.00%	100.00%	100.00%	100.00%	100.00%		- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
74.79%	74.79%	74.79%	74.79%	74.79%	74.79%		- Percentage of shares (as a % of the total share capital of the company)	74.79%	74.79%	74.79%	74.79%	74.79%

Particulars	3 months ended 31/12/2014
B	
INVESTOR COMPLAINTS [In Numbers]	
Pending at the beginning of the quarter	Nil
Received during the quarter	7
Disposed of during the quarter	7
Remaining unresolved at the end of the quarter	Nil

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R. Patel
Chairman & Managing Director